Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep;56(9):4583-5.
doi: 10.1128/AAC.06311-11. Epub 2012 Jun 11.

Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval

Aylin Yilmaz  1 , Victoria Watson, Laura Dickinson, David Back
Affiliations

Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval

Aylin Yilmaz et al. Antimicrob Agents Chemother. 2012 Sep.

Abstract

We determined the pharmacokinetics of efavirenz in plasma and cerebrospinal fluid (CSF) over a 24-h dosing interval in a patient who had undergone a lumbar drain because of cryptococcal meningitis. Drug concentrations were determined by high-performance liquid chromatography-tandem mass spectrometry in paired CSF (n = 24) and plasma (n = 25) samples. The median plasma efavirenz concentration was 3,718 ng/ml (range, 2,439 to 4,952), and the median CSF concentration was 16.3 ng/ml (range, 7.3 to 22.3). The CSF/plasma area-under-the-curve ratio was 0.0044 corresponding to a CSF penetration of 0.44% of plasma.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Efavirenz concentrations in CSF and plasma over a 24-h dosing interval.
Fig 2
Fig 2
Schematic of efavirenz transfer through plasma and CSF compartments.
See this image and copyright information in PMC

References

    1. Acosta E, et al. 2011. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA
    1. Antinori A, et al. 2005. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin. Infect. Dis. 41:1787–1793 - PubMed
    1. Best BM, et al. 2010. Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J. Antimicrob. Chemother. 66:354–357 - PMC - PubMed
    1. Cysique LA, Maruff P, Brew BJ. 2004. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J. Neurovirol. 10:350–357 - PubMed
    1. d'Arminio Monforte A, et al. 2004. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann. Neurol. 55:320–328 - PubMed

Publication types

MeSH terms